CEL-SCI Corporation

Type: Public
On the web: http://www.cel-sci.com
Employees: 26

CEL-SCI hopes to make L.E.A.P.S. and bounds in preventing and treating deadly diseases. Its L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology modulates T-cells and may lead to synthetic vaccines for herpes, viral encephalitis, smallpox, and other diseases; the National Institutes of Health is testing CEL-1000 (a compound developed using L.E.A.P.S. technology) as a potential avian flu vaccine. The firm's lead drug candidate, however, is Multikine, which might make tumors more susceptible to radiation therapy and help a patient's body produce tumor-fighting antibodies; it is undergoing clinical trials for the treatment of head and neck tumors.

Key numbers for fiscal year ending September, 2007:
Sales: $0.1M
One year growth: (53.8%)
Net income: ($9.6)M

Officers:
Chairman and President: Maximilian de Clara
CEO, Treasurer, and Director: Geert R. Kersten
SVP Operations and Secretary: Patricia B. Prichep

Competitors:
Chiron
IDM
Introgen Therapeutics

Complex vertebral malformation.